Rain Therapeutics, RAIN is showing recent insider trading activity. Public SEC records indicate that KEVIN TANG recently Bought $83,304 worth of shares on 3 days ago. With that said, our editors here at politicsandwallstreet.com, are adding RAIN to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of RAIN that Bought 21,155,585 worth of shares in the last 3 months, the Insider Confidence level of Rain Therapeutics is trending Up.
Since these insiders have unique insights into what's happening at Rain Therapeutics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for RAIN:
In addition, TradingView issued a buy rating for RAIN over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook.
Yigal Nochomovitz
Here is a bit more on Rain Therapeutics, RAIN but please do your own research.
RAIN Summary: Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc., formerly known as Rain Therapeutics Inc., is based in NEWARK, Calif.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to RAIN, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of RAIN that Bought 21,155,585 worth of shares in the last 3 months, the Insider Confidence level of Rain Therapeutics is trending Up.
Since these insiders have unique insights into what's happening at Rain Therapeutics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for RAIN:
- KEVIN TANG - 10 percent owner, Bought $83,304 worth of shares on 3 days ago
- KEVIN TANG - 10 percent owner, Bought $47,011 worth of shares on 3 days ago
- KEVIN TANG - 10 percent owner, Bought $51,464 worth of shares on 4 days ago
- KEVIN TANG - 10 percent owner, Bought $24,684 worth of shares on 4 days ago
In addition, TradingView issued a buy rating for RAIN over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook.
Yigal Nochomovitz
Here is a bit more on Rain Therapeutics, RAIN but please do your own research.
RAIN Summary: Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc., formerly known as Rain Therapeutics Inc., is based in NEWARK, Calif.
- Recent Last Price: $1.06
- Price Change: $0.07, 7.07%
- Yearly Gain: -80.51%
- Market Cap: $27.30M
- P/E Ratio: -0.387
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to RAIN, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
